Quick Answer
Kairos Pharma, LTD. reported Stockholders Equity of $6.34 million for fiscal year 2025.
Kairos Pharma, LTD. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.34M | +32.8% |
| 2024 | $4.78M | +329.8% |
| 2023 | -$2.08M | -76.3% |
| 2022 | -$1.18M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.66M | +130.0% | +27.8% |
| June 30, 2025 | $6.00M | +326.0% | -15.9% |
| March 31, 2025 | $7.13M | +397.0% | +49.3% |
| December 31, 2024 | $4.78M | +329.8% | +43.3% |
| September 30, 2024 | $3.33M | +277.9% | +225.5% |
| June 30, 2024 | -$2.65M | -70.0% | -10.5% |
| March 31, 2024 | -$2.40M | — | -15.5% |
| December 31, 2023 | -$2.08M | -76.3% | -10.9% |
- Kairos Pharma, LTD. showed an increase of +32.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Kairos Pharma, LTD.’s stockholders equity has grown by 637.8% (from -$1.18 million to $6.34 million).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: